Limits...
Differential methylation pattern of ID4, SFRP1, and SHP1 between acute myeloid leukemia and chronic myeloid leukemia.

Uhm KO, Lee ES, Lee YM, Park JS, Kim SJ, Kim BS, Kim HS, Park SH - J. Korean Med. Sci. (2009)

Bottom Line: Also, we compared the methylation status of genes in AML and CML using methylation-specific PCR (MSP).The frequencies of DNA methylation of ID4, SFRP1, and SHP1 were higher in AML patients compared to those in CML patients.Taken together, these results suggest that these methylation-controlled genes may have different roles in AML and CML, and thus, may act as a biological marker of AML.

View Article: PubMed Central - PubMed

Affiliation: Institute of Human Genetics, Department of Anatomy, Brain Korea 21 Biomedical Sciences, Korea University College of Medicine, Seoul, Korea.

ABSTRACT
To gain insight into the differential mechanism of gene promoter hypermethylation in acute and chronic leukemia, we identified the methylation status on one part of 5'CpG rich region of 8 genes, DAB2IP, DLC-1, H-cadherin, ID4, Integrin alpha4, RUNX3, SFRP1, and SHP1 in bone marrows from acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) patients. Also, we compared the methylation status of genes in AML and CML using methylation-specific PCR (MSP). The frequencies of DNA methylation of ID4, SFRP1, and SHP1 were higher in AML patients compared to those in CML patients. In contrast, no statistical difference between AML and CML was detected for other genes such as DLC-1, DAB2IP, H-cadherin, Integrin alpha4, and RUNX3. Taken together, these results suggest that these methylation-controlled genes may have different roles in AML and CML, and thus, may act as a biological marker of AML.

Show MeSH

Related in: MedlinePlus

PCR product images of the DAB2IP, DLC-1, H-Cadherin, ID4, Integrin α4, RUNX3, SFRP1, and SHP1 genes in normal peripheral bloods, acute myeloid leukemias, and chronic myeloid leukemias.N, normal peripheral blood; A, acute myeloid leukemia; C, chronic myeloid leukemias; U, amplified products used as primers for the unmethylated sequence in normal peripheral blood; M, amplified products used as primers for the methylated sequence.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2698198&req=5

Figure 1: PCR product images of the DAB2IP, DLC-1, H-Cadherin, ID4, Integrin α4, RUNX3, SFRP1, and SHP1 genes in normal peripheral bloods, acute myeloid leukemias, and chronic myeloid leukemias.N, normal peripheral blood; A, acute myeloid leukemia; C, chronic myeloid leukemias; U, amplified products used as primers for the unmethylated sequence in normal peripheral blood; M, amplified products used as primers for the methylated sequence.

Mentions: The multiple genes were found to be methylated in bone marrow from patients with AML or CML. Specifically, the frequencies of promoter hypermethylation at selected locus in the 23 AML samples were: 78.3% (18/23) for SHP1, 65.2% (15/23) for ID4 and SFRP1, 26.1% (6/23) for H-cadherin, 8.7% (2/23) for DLC-1, and 4.3% (1/23) for DAB2IP and RUNX3. The frequencies of DNA hypermethylation at selected locus in the 21 CML samples were: 28.6% (6/21) for SHP1, 19.0% (4/21) for H-Cadherin, 14.3% (3/21) for ID4, 9.5% for (2/21) for SFRP1, and 0% (0/21) for DAB2IP, DLC-1, Integrin α4, and RUNX3 (Fig. 1). However, promoter hypermethylation of the 22 normal peripheral bloods was observed less frequently (Table 2).


Differential methylation pattern of ID4, SFRP1, and SHP1 between acute myeloid leukemia and chronic myeloid leukemia.

Uhm KO, Lee ES, Lee YM, Park JS, Kim SJ, Kim BS, Kim HS, Park SH - J. Korean Med. Sci. (2009)

PCR product images of the DAB2IP, DLC-1, H-Cadherin, ID4, Integrin α4, RUNX3, SFRP1, and SHP1 genes in normal peripheral bloods, acute myeloid leukemias, and chronic myeloid leukemias.N, normal peripheral blood; A, acute myeloid leukemia; C, chronic myeloid leukemias; U, amplified products used as primers for the unmethylated sequence in normal peripheral blood; M, amplified products used as primers for the methylated sequence.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2698198&req=5

Figure 1: PCR product images of the DAB2IP, DLC-1, H-Cadherin, ID4, Integrin α4, RUNX3, SFRP1, and SHP1 genes in normal peripheral bloods, acute myeloid leukemias, and chronic myeloid leukemias.N, normal peripheral blood; A, acute myeloid leukemia; C, chronic myeloid leukemias; U, amplified products used as primers for the unmethylated sequence in normal peripheral blood; M, amplified products used as primers for the methylated sequence.
Mentions: The multiple genes were found to be methylated in bone marrow from patients with AML or CML. Specifically, the frequencies of promoter hypermethylation at selected locus in the 23 AML samples were: 78.3% (18/23) for SHP1, 65.2% (15/23) for ID4 and SFRP1, 26.1% (6/23) for H-cadherin, 8.7% (2/23) for DLC-1, and 4.3% (1/23) for DAB2IP and RUNX3. The frequencies of DNA hypermethylation at selected locus in the 21 CML samples were: 28.6% (6/21) for SHP1, 19.0% (4/21) for H-Cadherin, 14.3% (3/21) for ID4, 9.5% for (2/21) for SFRP1, and 0% (0/21) for DAB2IP, DLC-1, Integrin α4, and RUNX3 (Fig. 1). However, promoter hypermethylation of the 22 normal peripheral bloods was observed less frequently (Table 2).

Bottom Line: Also, we compared the methylation status of genes in AML and CML using methylation-specific PCR (MSP).The frequencies of DNA methylation of ID4, SFRP1, and SHP1 were higher in AML patients compared to those in CML patients.Taken together, these results suggest that these methylation-controlled genes may have different roles in AML and CML, and thus, may act as a biological marker of AML.

View Article: PubMed Central - PubMed

Affiliation: Institute of Human Genetics, Department of Anatomy, Brain Korea 21 Biomedical Sciences, Korea University College of Medicine, Seoul, Korea.

ABSTRACT
To gain insight into the differential mechanism of gene promoter hypermethylation in acute and chronic leukemia, we identified the methylation status on one part of 5'CpG rich region of 8 genes, DAB2IP, DLC-1, H-cadherin, ID4, Integrin alpha4, RUNX3, SFRP1, and SHP1 in bone marrows from acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) patients. Also, we compared the methylation status of genes in AML and CML using methylation-specific PCR (MSP). The frequencies of DNA methylation of ID4, SFRP1, and SHP1 were higher in AML patients compared to those in CML patients. In contrast, no statistical difference between AML and CML was detected for other genes such as DLC-1, DAB2IP, H-cadherin, Integrin alpha4, and RUNX3. Taken together, these results suggest that these methylation-controlled genes may have different roles in AML and CML, and thus, may act as a biological marker of AML.

Show MeSH
Related in: MedlinePlus